How to Get Rezdiffra (Resmetirom) in Rhode Island

Who Qualifies for Rezdiffra in Rhode Island

Rezdiffra is FDA-approved for adults with noncirrhotic MASH and moderate to advanced hepatic fibrosis, classified as stages F2 or F3. The FDA prescribing information specifies that fibrosis staging must be confirmed through liver biopsy or a validated noninvasive test such as transient elastography (FibroScan). Rhode Island insurers follow these same criteria when evaluating prior authorization requests.

A diagnosis of MASH alone is not sufficient. The fibrosis component matters. Patients with stage F1 fibrosis or those with compensated cirrhosis (F4) fall outside the current labeled indication. Rhode Island Medicaid's prior authorization form explicitly asks for documentation of fibrosis stage, and commercial plans in the state mirror this requirement. The AASLD practice guidance on MASLD recommends noninvasive testing as a first-line screening tool, which most Rhode Island hepatology practices now use as standard of care.

Your prescriber will also need to rule out other causes of liver disease. Alcohol-associated liver disease, viral hepatitis, and autoimmune conditions must be excluded or adequately managed before initiating resmetirom. This is not a bureaucratic hoop. The MAESTRO-NASH trial excluded patients with significant alcohol use (defined as more than 20 g/day for women and 30 g/day for men) and those with decompensated liver disease [1].

The MAESTRO-NASH Trial: What the Evidence Shows

The data behind Rezdiffra comes primarily from MAESTRO-NASH, a phase 3, randomized, double-blind trial published in the New England Journal of Medicine in February 2024. The trial enrolled 966 participants with biopsy-confirmed MASH and fibrosis stages F1B through F3 across 200 sites [1].

At 52 weeks, 26% of patients receiving the 80 mg dose achieved MASH resolution with no worsening of fibrosis, compared to 10% on placebo. That is a 16-percentage-point absolute difference. The 100 mg dose produced a 30% resolution rate [1]. Fibrosis improvement of at least one stage without MASH worsening occurred in 26% of the 80 mg group and 24% of the 100 mg group, versus 14% on placebo.

These numbers earned resmetirom its accelerated approval. Full approval depends on confirmatory data showing clinical benefit, meaning fewer liver-related events over time. For Rhode Island clinicians deciding whether to prescribe, the NNT (number needed to treat) for MASH resolution is approximately 6 for the 80 mg dose. That compares favorably to many therapies used in hepatology.

Side effects in MAESTRO-NASH were predominantly gastrointestinal. Diarrhea occurred in 27% of the 80 mg group versus 16% on placebo, and nausea in 22% versus 13% [1]. Most events were mild to moderate and resolved within the first 12 weeks of treatment. No signal for serious hepatotoxicity emerged, though the FDA label requires monitoring of liver enzymes.

Dr. Stephen Harrison, principal investigator of the MAESTRO-NASH trial, stated: "Resmetirom represents the first approved pharmacotherapy specifically targeting the metabolic dysfunction that drives MASH progression. The liver-directed thyroid hormone receptor beta agonism addresses a mechanism distinct from weight loss drugs" [1].

How to Get a Rezdiffra Prescription in Rhode Island

Rhode Island permits licensed prescribers to write Rezdiffra prescriptions through both traditional office visits and telehealth consultations. The state's telehealth parity law (R.I. Gen. Laws § 27-81) requires insurers to cover telehealth services on the same terms as in-person visits, which simplifies the prescribing pathway for patients outside the Providence metro area.

Three practical routes exist:

1. Hepatologist or gastroenterologist referral. Rhode Island has hepatology practices concentrated in Providence, Warwick, and Cranston. Lifespan Health System and Care New England both operate liver disease clinics that are prescribing resmetirom. A referral from your primary care provider typically takes 1 to 3 weeks for scheduling.

2. Telehealth consultation. Licensed telehealth platforms operating in Rhode Island can prescribe Rezdiffra if the provider holds a valid Rhode Island medical license or a license recognized under an interstate compact. The prescriber must review qualifying labs and imaging before writing the prescription. Rhode Island does not require an initial in-person visit for specialty medications prescribed via telehealth, which removes a barrier that exists in some other states.

3. Primary care initiation with specialist oversight. Some Rhode Island PCPs are comfortable initiating resmetirom for patients who arrive with documented FibroScan results and a confirmed MASH diagnosis. This is less common but not prohibited. The Endocrine Society's 2023 clinical practice guideline on MASLD management supports a collaborative care model between primary care and hepatology for metabolic liver disease.

Regardless of the route, you will need recent lab work. Do not schedule a prescribing appointment without it.

Lab Work and Diagnostic Testing Required Before Prescribing

Rhode Island prescribers and insurance companies require specific documentation before initiating Rezdiffra. Missing a single lab can delay prior authorization by weeks.

Mandatory before first prescription:

Liver function panel (ALT, AST, ALP, total bilirubin, albumin) drawn within 90 days. The FDA label mandates baseline liver tests and repeat testing at months 3, 6, and 12. ALT must be below 5 times the upper limit of normal to initiate treatment.

Fibrosis assessment confirming stage F2 or F3. FibroScan (vibration-controlled transient elastography) is the most widely used noninvasive method in Rhode Island. A liver stiffness measurement between 8.0 and 13.9 kPa generally corresponds to F2-F3, depending on the etiology-specific cutoffs. Liver biopsy remains the reference standard but is rarely required by Rhode Island insurers if FibroScan results are clear.

Lipid panel. Resmetirom lowers LDL cholesterol by approximately 14% at the 80 mg dose, a secondary benefit observed in MAESTRO-NASH [1]. Baseline lipids help track this effect and may influence co-prescribing decisions.

TSH level. Although resmetirom selectively targets thyroid hormone receptor beta and does not cause clinical hyperthyroidism, the FDA label recommends baseline thyroid function testing.

Recommended but not always required:

Complete blood count, hemoglobin A1c (given the high overlap between MASH and type 2 diabetes), and a hepatitis B/C panel to rule out viral causes. The CDC's universal hepatitis B screening recommendation applies here.

Approximately 60% of MASH patients have concurrent type 2 diabetes, according to data from the NHANES analysis published in Diabetes Care. Rhode Island prescribers routinely screen for this overlap because GLP-1 receptor agonists may offer complementary benefit.

Prior Authorization in Rhode Island: Step by Step

Rhode Island Medicaid covers Rezdiffra with prior authorization. Most commercial plans in the state, including Blue Cross Blue Shield of Rhode Island and Neighborhood Health Plan of Rhode Island, also require PA. The process follows a predictable pattern.

Step 1: Prescriber submits PA request. This includes the ICD-10 code for MASH (K75.81), fibrosis stage documentation, recent liver labs, and a statement confirming the patient meets FDA-labeled criteria. Rhode Island Medicaid uses a standardized PA form available through the state's pharmacy benefit manager.

Step 2: Insurer review. Rhode Island Medicaid must respond within 24 hours for urgent requests and 72 hours for standard requests under state regulation. Commercial insurers generally take 5 to 14 business days.

Step 3: Approval, denial, or request for additional information. If denied, Rhode Island law guarantees an appeal process. The most common denial reason is insufficient fibrosis documentation. A FibroScan report with a clearly stated kPa value and fibrosis stage interpretation reduces denial rates significantly.

Step 4: Prescription routed to specialty pharmacy. Rezdiffra is distributed through specialty pharmacy channels. Accredo, CVS Specialty, and Optum Specialty are the most common dispensing pharmacies for Rhode Island patients. Some prescriptions route through Madrigal Pharmaceuticals' patient support program (Madrigal Connect), which assists with copay and access navigation.

The American Association of Clinical Endocrinology (AACE) 2023 consensus statement on MASLD emphasizes that payer barriers should not delay treatment in patients with progressive fibrosis, as the risk of cirrhosis advancement increases with each year of untreated F2-F3 disease.

Dr. Zobair Younossi, a leading MASH researcher and chair of the Global NASH Council, has noted: "Every 12 months of delayed treatment in a patient with F3 fibrosis represents a measurable increase in the probability of progression to cirrhosis and liver-related mortality" [2].

Pharmacy Access and 503A Compounding in Rhode Island

Rezdiffra is commercially available as a branded product from Madrigal Pharmaceuticals. Standard dispensing occurs through specialty pharmacies, not retail chains. Rhode Island patients should expect home delivery in most cases, with typical shipping times of 2 to 5 business days after PA approval.

Rhode Island also licenses 503A compounding pharmacies that may prepare resmetirom formulations. Under federal law (section 503A of the Federal Food, Drug, and Cosmetic Act), a 503A pharmacy can compound a drug for an individual patient based on a valid prescription if certain conditions are met. The pharmacy must be licensed in Rhode Island, and the compounded product must not be a copy of a commercially available drug unless the prescriber documents a clinical need for a modified formulation (such as a different strength or dosage form).

In practice, most Rhode Island patients will receive brand-name Rezdiffra through the specialty pharmacy channel. Compounding becomes relevant in limited scenarios: patients who cannot swallow tablets, pediatric off-label use (not FDA-approved), or situations where the commercially available strengths (60 mg, 80 mg, 100 mg tablets) do not meet the prescriber's dosing needs.

Rhode Island's Board of Pharmacy maintains a public database of licensed pharmacies, including those with compounding permits. Patients can verify a pharmacy's licensure status before transferring a prescription.

Telehealth Prescribing Rules Specific to Rhode Island

Rhode Island's telehealth framework is among the more permissive in New England. Key provisions that affect Rezdiffra access include the following.

No in-person visit requirement for initial prescriptions. Unlike some states that mandate at least one face-to-face encounter before prescribing specialty medications, Rhode Island allows a fully virtual evaluation for Rezdiffra. The prescriber must conduct a synchronous audio-video consultation, not audio-only, for the initial visit per Rhode Island Department of Health telemedicine guidelines.

Interstate practice. Providers licensed through the Interstate Medical Licensure Compact (IMLC) can treat Rhode Island patients without obtaining a separate Rhode Island license. Rhode Island joined the IMLC in 2017. This expands the pool of available prescribers, which matters because hepatology is a subspecialty with limited local availability in smaller states.

Prescribing controlled substances versus non-controlled. Resmetirom is not a controlled substance, which removes additional telehealth prescribing restrictions that apply to Schedule II through V drugs in Rhode Island. No DEA-specific telehealth waiver is needed.

Follow-up monitoring can also occur via telehealth. The FDA-required liver function monitoring at 3, 6, and 12 months can be reviewed virtually as long as the patient obtains blood work at a local lab. Quest Diagnostics and Labcorp both have multiple draw sites in Rhode Island, and many patients can use mobile phlebotomy services.

Cost, Copay Assistance, and Financial Navigation

Rezdiffra's wholesale acquisition cost (WAC) is approximately $47,400 per year. Out-of-pocket costs vary widely depending on insurance.

Rhode Island Medicaid patients approved through prior authorization typically pay $0 to $3 per fill, consistent with the state's Medicaid copay structure for specialty drugs.

Commercial insurance copays range from $25 to $250 per month for patients with specialty tier coverage. Many Rhode Island commercial plans place Rezdiffra on specialty tier 5, which often carries a percentage-based coinsurance rather than a flat copay.

Madrigal Pharmaceuticals operates the Madrigal Connect copay assistance program, which can reduce commercially insured patients' out-of-pocket costs to as low as $0 per month. The program is not available to patients with government insurance (Medicaid, Medicare, Tricare, VA). Enrollment requires a valid Rezdiffra prescription and proof of commercial coverage.

For uninsured Rhode Island patients, Madrigal offers a patient assistance program with income-based eligibility. Patients at or below 400% of the federal poverty level (approximately $62,400 for a single individual in 2026) may qualify for free medication.

The NIH's MASLD burden analysis estimates that untreated MASH progressing to cirrhosis generates average lifetime costs exceeding $180,000 per patient in direct medical expenses. Early pharmacotherapy, while expensive, may offset downstream costs from liver transplantation, hepatocellular carcinoma screening, and decompensation management.

Transferring a Rezdiffra Prescription to Rhode Island

Patients relocating to Rhode Island or receiving care from an out-of-state provider can transfer an existing Rezdiffra prescription. Rhode Island accepts prescription transfers from all 50 states for non-controlled medications. The process involves the receiving pharmacy contacting the originating pharmacy to verify and transfer the prescription record.

One caveat: prior authorization does not transfer between insurance plans. If you change insurers during a move to Rhode Island, your new plan will require a fresh PA. Ask your prescriber to keep copies of your FibroScan report and lab work to expedite resubmission. A lapse in Rezdiffra treatment is not medically dangerous in the short term, but interruptions beyond 4 to 6 weeks may require your prescriber to repeat baseline liver function testing per the FDA label.

Specialty pharmacies that participate in Madrigal's distribution network can typically coordinate the transfer within 3 to 5 business days. Contact Madrigal Connect at the number listed on your medication packaging for transfer assistance.

Monitoring and Follow-Up After Starting Rezdiffra

Rhode Island prescribers follow the FDA-mandated monitoring schedule. This is not optional.

Liver function tests (ALT, AST, bilirubin) at baseline, month 3, month 6, and month 12. If ALT rises above 5 times the upper limit of normal, the drug must be discontinued. In MAESTRO-NASH, ALT elevations above this threshold occurred in fewer than 1% of treated patients [1].

Repeat fibrosis assessment at 12 months is recommended to evaluate treatment response. A reduction in liver stiffness of 20% or more on FibroScan, or improvement of at least one fibrosis stage on biopsy, indicates a positive response.

Lipid monitoring every 6 months. The LDL-lowering effect of resmetirom may allow dose reduction of concurrent statin therapy in some patients, though this should be decided collaboratively between the patient's hepatologist and cardiologist.

Weight and metabolic parameters. Resmetirom is not a weight-loss drug, but modest weight reduction (2 to 3 kg on average) was observed in MAESTRO-NASH. Patients using concurrent GLP-1 agonists, which is increasingly common in the MASH population, should have their metabolic panel monitored for additive effects on glucose and lipids.

The initial Rezdiffra dose is 80 mg once daily for patients weighing less than 100 kg, and 100 mg once daily for those at or above 100 kg. Dose adjustments based on weight changes during treatment should be discussed at follow-up visits.